


Pirimenol

Cat. No.:	HY-100795
CAS No.:	68252-19-7
Molecular Formula:	C ₂₂ H ₃₀ N ₂ O
Molecular Weight:	338.49
Target:	mAChR; Potassium Channel
Pathway:	GPCR/G Protein; Neuronal Signaling; Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Pirimenol is an orally active antiarrhythmic agent. Pirimenol inhibits I _{K,ACh} (IC ₅₀ : 0.1 μM) by blocking mAChR. Pirimenol can be used in the research of cardiovascular disease, such as atrial fibrillation ^{[1][2][4]} .								
IC₅₀ & Target	IC ₅₀ : 0.1 μM (I _{K,ACh}) ^[1]								
In Vitro	<p>Pirimenol (1 μM) inhibits the I_{K,ACh} induced by carbachol or intracellular loading of GTPγS in in atrial cells^[1].</p> <p>Pirimenol (5 μM) depresses the early part of the plateau and lengthened the final repolarization of the action potentials in ventricular myocytes^[3].</p> <p>Pirimenol (1 μM) prolongs the action potential duration at 90% repolarization in atrial muscles and Purkinje fibers^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>Pirimenol (2.5 and 5 mg/kg, p.o.) is effective against the arrhythmias in conscious, coronary artery ligated dogs^[4].</p> <p>Pirimenol (rats) shows LD₅₀s of 359.9 mg/kg (p.o), 23.6 mg/kg (i.v.)^[2].</p> <p>Pirimenol (mice) shows LD₅₀s of 215.5 mg/kg (p.o), 20.8 mg/kg (i.v.)^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Conscious, coronary artery ligated dogs^[4]</td> </tr> <tr> <td>Dosage:</td> <td>Oral administration (p.o.)</td> </tr> <tr> <td>Administration:</td> <td>2.5 and 5 mg/kg</td> </tr> <tr> <td>Result:</td> <td>Restored normal sinus rhythm, and showed a long duration of activity, wide safety margin.</td> </tr> </table>	Animal Model:	Conscious, coronary artery ligated dogs ^[4]	Dosage:	Oral administration (p.o.)	Administration:	2.5 and 5 mg/kg	Result:	Restored normal sinus rhythm, and showed a long duration of activity, wide safety margin.
Animal Model:	Conscious, coronary artery ligated dogs ^[4]								
Dosage:	Oral administration (p.o.)								
Administration:	2.5 and 5 mg/kg								
Result:	Restored normal sinus rhythm, and showed a long duration of activity, wide safety margin.								

REFERENCES

- [1]. T Sawanobori, et al. Electrophysiologic and antiarrhythmic actions of pirimenol on rabbit and guinea pig cardiac preparations. J Cardiovasc Pharmacol. 1990 Dec;16(6):975-83.
- [2]. T E Mertz, et al. Pirimenol hydrochloride (CI-845): antiarrhythmic profile in coronary artery ligated conscious dogs. J Cardiovasc Pharmacol. 1980 Sep-Oct;2(5):527-41.
- [3]. Watanabe Y, et al. Pirimenol inhibits muscarinic acetylcholine receptor-operated K⁺ current in the guinea pig heart. Eur J Pharmacol. 1997 Oct 29;338(1):71-4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA